在加拿大Novo Nordisk发射更廉价、重塑品牌的Ozempic和Wegovy, 以对抗非专利物并改善准入。 Novo Nordisk launches cheaper, rebranded Ozempic and Wegovy in Canada to fight generics and improve access.

诺沃·诺迪斯克正在探索加拿大市场的低价、更名的Ozempic和Wegovy-Plosbrio和Poviztra版本,以对付即将到来的非专利硫酸盐药物。 Novo Nordisk is exploring lower-priced, renamed versions of Ozempic and Wegovy—Plosbrio and Poviztra—for the Canadian market to counter upcoming generic semaglutide drugs. 加拿大卫生部批准了关于这些生物相同的产品的呈件,这些产品绕过了冗长的一般性审查程序。 Health Canada has approved the submissions for these biologically identical products, which bypass the lengthy generic review process. 与此相反,来自Sandoz、Apotex、Teva、Taro和Aspen药房的化学合成非专利药物仍在评估中。 In contrast, chemically synthesized generics from Sandoz, Apotex, Teva, Taro, and Aspen Pharmacare are still under evaluation. 这一举动被视为一种战略定价策略,在非专利药的压力下维持市场份额,有可能改善患者获得治疗的机会,尽管目前的价格很高。 The move is seen as a strategic pricing tactic to maintain market share amid pressure from generics, potentially improving patient access despite high current prices. 大多数加拿大病人都被纳入保险或公共计划, 但未投保的个人仍可以通过诺沃·诺迪斯克的援助方案获得支持。 Most Canadian patients are covered by insurance or public plans, but uninsured individuals can still receive support through Novo Nordisk’s assistance programs.